Akèy › Kansè Ezofajyen › Pennsylvania › Pittsburgh
Etid klinik pou Kansè Ezofajyen nan Pittsburgh, PA
15 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan ak bò kote Pittsburgh (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Ap rekriteFaz 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Ap rekriteFaz 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
Ap rekrite
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
Esophageal Cancer Risk Registry
Ap rekriteEtid obsèvasyon
- Department of Cardiothoracic Surgery, Pittsburgh
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
Ap rekriteEtid obsèvasyon
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh
- UPMC - Hillman Cancer Center, Pittsburgh
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Ap rekriteEtid obsèvasyon
- Allegheny Health Network, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Ap rekriteFaz 1
- AHN West Penn Hospital, Pittsburgh
Etid Kansè Ezofajyen nan lòt vil
- Houston, TX36 etid
- Boston, MA23 etid
- New York City, NY22 etid
- Nashville, TN19 etid
- St. Louis, MO17 etid
- Los Angeles, CA15 etid
- Baldwin Park, CA14 etid
- Grand Rapids, MI14 etid
- Philadelphia, PA13 etid
- San Antonio, TX12 etid
- Dallas, TX11 etid
- Arlington, VA11 etid
Lòt etid nan Pittsburgh
- Kansè Poumon ki pa ti selil48 etid
- Kansè (tout kalite)41 etid
- Kansè nan tete39 etid
- Kansè kolorektal32 etid
- Kansè Metastatik31 etid
- Melanom31 etid
- Kansè ovè30 etid
- Kansè Endomèt23 etid
- Kansè pwostat23 etid
- Kansè poumon23 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
- Akidan serebavaskilè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.